Merck: The Vioxx Safety Pitch and the Public Bill

The Merck Vioxx government settlement included a $628,364,000 civil agreement over alleged off-label promotion and false cardiovascular-safety statements. The government alleged that Merck’s sales pitch helped generate federal payments and that its safety claims influenced state Medicaid agencies deciding whether to pay for the drug. For someone inside pharmaceutical sales, medical affairs or regulatory review, the case connects familiar work to the public bill: what the company promoted, what supported its safety message, and who relied on it.

The Department of Justice announced the agreement on November 22, 2011. Merck Sharp & Dohme sold Vioxx, also called rofecoxib, as a painkiller. The company had withdrawn it from the market in September 2004.

Among pharmaceutical fraud cases, Vioxx shows why the words used to sell a drug can matter to the government paying for it. The allegations reached both the use being promoted and the reassurance given about its safety.

What Is Considered Off-Label Promotion?

Off-label promotion means promoting a drug for a use outside its Food and Drug Administration approval. The Vioxx example was rheumatoid arthritis: the government alleged that Merck promoted that use before the agency approved it.

The agency first approved Vioxx for three indications in May 1999. Rheumatoid arthritis was not approved until April 2002. In between, according to the Justice Department’s account of Merck’s criminal plea, Merck promoted Vioxx for rheumatoid arthritis for nearly three years. That account says the agency issued a warning letter about that conduct.

The date on a promotional piece matters because the approval for that use may have come later.

The civil settlement connected the promotion to allegedly false claims for payment. That connection is central to off-label promotion and pharmaceutical false claims: the commercial instruction, the resulting prescription and the government payment belong in the same account. Here, the government specifically sought damages for allegedly false claims caused by promotion for rheumatoid arthritis.

For an insider, the warning letter also gives the story a concrete point of comparison. The sales message before the warning, the company’s response and the material used afterward can show how a regulatory objection was handled inside the business.

Cardiovascular Safety Claims Reached the People Paying

The Vioxx civil settlement covered alleged false statements about cardiovascular safety as well as promotion for an unapproved use. The government described distinct ways those statements reached public money.

First, it alleged that Merck representatives made inaccurate, unsupported or misleading safety statements to increase sales, resulting in federal payments. Second, it alleged that Merck made false safety statements directly to state Medicaid agencies, which relied on them when making payment decisions about Vioxx.

The Medicaid allegation puts the safety message directly in front of the people deciding whether public money would pay for the drug. Merck allegedly gave those agencies false information about the risks of the product they were being asked to cover. Taxpayers funded the health care program, and patients took the drug.

The pharmaceutical business separates selling the drug from submitting the prescription claim. A manufacturer can influence the prescription while a pharmacy or physician submits the claim. The False Claims Act reaches a company that causes false claims to be submitted, which is why the connection between the manufacturer’s conduct and the paid prescription matters here.

The safety literature adds an uncomfortable comparison. A review from the Nordic Cochrane Centre, Corporate Crime in the Pharmaceutical Industry Is Common, Serious and Repetitive, published in 2012, describes a pamphlet Merck gave its sales force presenting Vioxx as having lower cardiovascular mortality than other anti-inflammatory drugs. The paper contrasts the pamphlet with the regulator’s concern about heart attacks:

In the paper’s account, the regulator’s concern became a safety advantage in the sales material.

For someone who worked on those materials, the comparison is between the scientific review and what the sales force received. The government’s civil allegations add the payment question: who relied on the message, and what did the government pay as a result?

The Civil Settlement Covered Federal and State Claims

The civil agreement allocated $426,389,000 to the United States, compared with $201,975,000 to participating Medicaid states. The federal share was larger, but the state payment put a price on the safety statements Medicaid agencies allegedly relied on.

Vioxx also appeared in an earlier Merck government case brought by a former employee. That case settled for $399 million over hospital discounts and physician-payment allegations. In its February 7, 2008 announcement, the Justice Department described allegations that Merck offered hospitals deep discounts on Zocor and Vioxx tied to use of those drugs in place of competing brands. The government alleged that Merck improperly treated hospital prices as nominal and excluded discounts from the prices reported to Medicaid.

That nominal-pricing and Medicaid-rebate case concerned what a hospital paid and what the manufacturer reported. The promotion case concerned what Merck said about the drug and the government payments those statements allegedly caused. The same product can appear in both while the underlying business records tell different stories.

Merck’s corporate integrity agreement with the Department of Health and Human Services’ Office of Inspector General required annual compliance certifications from top officials and public disclosure of physician payments. The product was gone. The company’s marketing operations remained.

Sales Targets Can Explain the Promotion

An allegation from the separate Endo Lidoderm case shows how an insider can connect a promotion campaign to decisions inside the company. The whistleblower’s complaint put the sales target itself at the center of the alleged conduct:

A quota is a business instruction. The complaint alleged that management set a target its representatives could reach only by promoting unapproved uses. That puts responsibility for the sales strategy inside the company setting the target.

For a case involving safety claims, the comparable business question is how the company turned its account of the science into the message representatives used. Training materials, promotional reviews and communications to public payers can connect the decision to the audience. An insider can explain how the company expected those materials to affect sales.

What Proof Do You Need as a Whistleblower?

For alleged promotion and safety-statement fraud, useful proof connects what the company said, what it knew and the government payments its conduct caused. We work with pharmaceutical whistleblowers to assess those connections in the context of their role and the records they know.

A sales employee may understand the instructions behind a call plan. A medical or regulatory employee may understand why a safety claim changed between review and distribution. Someone dealing with Medicaid may know what the company told the agency and which payment decision followed. These are different views of the same commercial chain, and they help us identify the decisions a qui tam case needs to explain.

The wider healthcare enforcement history shows the value of that inside account. In its 2018 report, Twenty-Seven Years of Pharmaceutical Industry Criminal and Civil Penalties: 1991 Through 2017, Public Citizen found that whistleblower revelations contributed at least in part to 54% of federal settlements with pharmaceutical manufacturers during the study period.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know How the Safety Message Was Made

If you know how a drug’s safety message changed on its way to the sales force or a Medicaid agency, speak with our whistleblower experts. We build the pharmaceutical fraud case with you, bring in pharmaceutical fraud whistleblower lawyers who understand promotion and government reimbursement, and stay beside you through the pursuit of a recovery.